Growth Hormone

FDA Approved

Tesamorelin

TESA

Stabilized GHRH analog studied in adipose research.

Also known as: Egrifta, TH9507

Research dose range1–2 mg daily (research models)

Route studiedSubcutaneous

Study durationDaily, multi-week studies

Storage2–8 °C reconstituted

Overview

Tesamorelin is a stabilized synthetic analog of growth-hormone-releasing hormone studied in adipose-tissue and metabolic research, particularly visceral-fat models.

Key research findings

The most clinically validated GHRH analog, FDA-approved for reduction of visceral adipose tissue in a specific population. Research reports preferential visceral-fat reduction with preservation of pulsatile, physiologic GH release rather than supraphysiologic spikes.

Mechanism of action

Binds GHRH receptors on the pituitary to stimulate endogenous, pulsatile growth-hormone release.

Molecular information

Weight5,135.9 Da

Length44 amino acids

TypeStabilized GHRH(1-44) analog

Amino-acid sequenceHuman GHRH(1-44) with an N-terminal trans-3-hexenoyl group for protease resistance.

The hexenoyl modification slows enzymatic degradation versus native GHRH.

Pharmacokinetics

Peak: ~0.15–0.25 hoursHalf-life: ~26–38 minutesCleared: ~6 hours

Peak · 2hHalf-life · 7h

Illustrative relative-concentration model derived from published pharmacokinetic research. Curve is normalized and provided for educational comparison only — not a dosing schedule.

Research applications

Visceral-adipose research
GH-axis and metabolic studies
Body-composition investigations

Research protocols

Protocols summarized from published research models. Provided for scientific reference only — not dosing guidance for human use.

Research goalReference amountFrequencyRoute

Standard referenceAmount: 1–2 mgFrequency: Once daily (evening)Route: Subcutaneous

Conservative referenceAmount: 1 mgFrequency: Once dailyRoute: Subcutaneous

Observed effects timeline

Aggregated observations reported across research literature. Timing and magnitude vary by model and are not a guarantee of outcome.

Week 1–2
Onset of increased GH pulse amplitude and IGF-1 reported in study cohorts.
Week 8–12
Measurable visceral-adipose reductions reported in research models.
Week 26+
Sustained visceral-fat reduction with stable IGF-1 reported over longer studies.

Research compatibility

Describes how compounds are studied alongside one another in the literature. Not a recommendation to co-administer.

Ipamorelin

Synergistic GH stimulation possible. Monitor IGF-1 levels closely and consider dose adjustments to prevent excessive growth hormone elevation.

Monitor

CJC-1295 (with DAC)

Redundant GHRH-receptor activation.

Avoid combination

HGH

Overlapping GH-axis effects in research models.

Use caution

BPC-157

Distinct pathways; co-studied in recovery contexts.

Compatible

CJC-1295 (No DAC)

Both bind to pituitary GHRH receptors. Combining saturates receptors without amplifying GH release, risking receptor desensitization and blunted pulsatility. Choose one based on your protocol goals.

Use caution

How to reconstitute

Important

Reconstitute with sterile or bacteriostatic water, swirl gently, and refrigerate. Tesamorelin is sensitive to heat and agitation.

1Allow the vial to reach room temperature (15–20 minutes).
2Swab the stopper with alcohol and let it air dry.
3Add the diluent slowly down the vial wall.
4Swirl gently until dissolved — never shake.
5Refrigerate at 2–8 °C and protect from light.

Open reconstitution calculator

Quality indicators

Uniform white powder

Lyophilized cake should be white to off-white with no discoloration.

Clear solution

Reconstitutes to a clear, colorless, particle-free solution.

Cold-chain integrity

Reconstituted solution requires 2–8 °C storage.

Slight clumping

Small clumps that dissolve completely with gentle swirling are acceptable — shipping can cause minor compaction.

Collapsed or melted appearance

Powder that looks collapsed, melted, or stuck to the vial walls may have been exposed to heat in transit.

Cloudy after reconstitution

Persistent cloudiness, particles, or precipitate after gentle mixing can indicate a degraded or contaminated peptide.

Reported observations & safety

Safety signals reported in the research literature. Compiled for scientific awareness — not medical advice.

Injection-site reactions are among the most commonly reported signals.
Joint discomfort, fluid retention, and glucose changes are reported with GH-axis stimulation.
IGF-1 monitoring is standard in research designs.

References & further reading

Tesamorelin for visceral adipose tissue (NEJM, 2007)

Humann=412visceral-fat reduction

Randomized trial reporting reductions in visceral adipose tissue with the GHRH analog over 26 weeks.

View study

Topics

ghrhgrowth hormoneadipose

This entry is provided for educational and informational purposes only. It is not medical advice, a dosing protocol, or a claim of therapeutic benefit. Research compounds are supplied strictly for laboratory and research use — not for human or veterinary consumption.

Research level

FDA Approved

Approved for one or more clinical indications by a major regulator.

Quick reference

Dose range1–2 mg daily (research models)

RouteSubcutaneous

DurationDaily, multi-week studies

Storage2–8 °C reconstituted

Half-life~26–38 minutes

Available at Reviva

Tesamorelin is stocked as a research-grade compound, ≥99% by HPLC, third-party verified.

View in catalogue